InsidersTradesSigma
Follow the Elite Pharmaceuticals INC stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Elite Pharmaceuticals INC has published 21 reports. Market capitalisation: €408.2m. The latest transaction was reported on 13 January 2026 (Levée d'options). Among the most active insiders: Plassche Douglas. Every trade is free.
21
Insider Decl.
n/a
Thresholds
€8,237
1 ops.
Buy Volume
€1m
4 ops.
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 548 of 29,063 companies
84.2
score / 100
Value81
Quality88
FCF yld5.9%
Earn yld12%
EV/EBITDA6.6x
ROE59%
Gross mgn50%
Net mgn30%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 13 January 2026
Declarations21 total
2,500,000 shares@ US$0.036.3% of flowStock Options (right to buy)SEC:0001493152-26-002062:0
800,000 shares@ US$0.62444.7% of flowcommon stockSEC:0001493152-25-016979:0
500,000 shares@ US$0.5243100.0% of flowCommon StockSEC:0001493152-25-012347:0
16,366 shares@ US$0.589100.0% of flowCommon StockSEC:0001946043-25-000002:0
Canonical exit: 8 Oct 2025 (T+90)
200,000 shares@ US$0.57918.8% of flowStock Options (right to buy)SEC:0001641172-25-018593:0
2,500,000 shares@ US$0.0314.9% of flowStock Options (right to buy)SEC:0001641172-25-018199:0
800,000 shares@ US$0.4985.1% of flowCommon StockSEC:0001493152-24-042726:0
49,534,368 shares0Common StockSEC:0001493152-24-012832:0
2,223,147 shares@ US$0.069100.0% of flowCommon StockSEC:0001583742-23-000001:0
547,657 shares@ US$0.036525.4% of flowCommon StockSEC:0001324222-23-000001:0
547,657 shares@ US$0.036525.4% of flowCommon StockSEC:0001324222-23-000003:0
547,657 shares@ US$0.036525.4% of flowCommon StockSEC:0001324222-23-000002:0
459,536 shares@ US$0.043527.9% of flowCommon StockSEC:0001324222-22-000003:0
459,536 shares@ US$0.043527.9% of flowCommon StockSEC:0001324222-22-000001:0
459,536 shares@ US$0.043527.9% of flowCommon StockSEC:0001324222-22-000002:0
295,570 shares@ US$0.067730.5% of flowCommon StockSEC:0001324222-21-000001:0
295,570 shares@ US$0.067730.5% of flowCommon StockSEC:0001324222-21-000002:0
295,570 shares@ US$0.067730.5% of flowCommon StockSEC:0001324222-21-000003:0
398,840 sharesCommon StockSEC:0001053369-16-000035:0
6,000,000 sharesCommon StockSEC:0001053369-16-000035:1
113,954 sharescommonSEC:0001442002-16-000001:0
21 of 21 declarations
关于 Elite Pharmaceuticals INC
Elite Pharmaceuticals, Inc. (ELTP) 是一家美国制药公司，其股票在美国 NASDAQ/NYSE 类型市场交易。该公司总部位于新泽西州诺斯维尔，于 1997 年根据特拉华州法律注册成立。Elite 围绕利基仿制药建立了业务，同时历史上也通过 NDA 途径寻求品牌开发项目。在其最近的 SEC 披露中，该公司表示其专注于制造已批准的基于 ANDA 的仿制产品，开发额外的仿制候选产品，并通过合作、许可、共同开发和相关的商业化安排推进选定的管线产品。Elite 还披露，它已暂停 NDA 项目的进一步开发，这表明其资本配置策略更加集中，并更加重视中短期商业机会。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001053369/000149315226007104/form10-q.htm?utm_source=openai)) 从竞争角度来看，Elite 最好被描述为一家专业制药公司，而不是一家大型综合制药商。其优势在于在较窄的产品市场中运营，在这些市场中，配方复杂性、监管专业知识和上市时机与规模同样重要。该公司的模式结合了自有品牌销售与许可和合作结构，这可以扩大覆盖范围，同时有助于分散开发风险。其核心商业足迹是美国，这也是其产品组合的关键监管市场。这种国内重点简化了投资者的叙述，但也意味着该公司仍然高度暴露于美国 FDA 批准、定价动态和仿制药竞争。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1053369/000164117225017134/form10-k.htm?utm_source=openai)) 最近的运营消息是积极的。截至 2025 年 3 月 31 日的财年，Elite 报告收入为 84.0 million 美元，同比增长约 48%，营业利润为 19.6 million 美元，同比增长约 81%。管理层将业绩改善主要归因于 2025 财年推出的利司地那非产品的销售以及前一财年推出的 Elite 品牌产品线的强劲增长。对于投资者而言，这表明该业务日益受益于产品发布和商业化势头，而不是仅仅依赖于长期开发里程碑。简而言之，ELTP 仍然是一家在美国上市的小盘制药公司，具有集中的仿制药专业概况、不断提高的经营杠杆以及与在美国的执行情况密切相关的商业模式。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1053369/000164117225017151/ex99-1.htm?utm_source=openai))
